SCHEMBL6152737

SCHEMBL6152737

N#CC1=CC=CC=CC=CC=CONN=NC=CC=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7743918 1.00
SCHEMBL7743917 1.00
SCHEMBL3639972 1.00
SCHEMBL12505719 0.77
SCHEMBL12505720 0.77
SCHEMBL24331905 0.71 CA1 (0.30)
SCHEMBL6415653 0.71 CA1 (0.30)
SCHEMBL3075840 0.60
SCHEMBL25057979 0.60
SCHEMBL9473501 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001051494-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2001-07-19 WO claimed
EP-1444209-A4 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2005-02-16 EP disclosed
EP-1496981-A2 METHOD OF TREATING CANCER Merck & Co., Inc. (US) 2005-01-19 EP disclosed
EP-1444209-A2 MITOTIC KINESIN INHIBITORS Merck & Co., Inc. (US) 2004-08-11 EP disclosed
WO-2003084473-A2 METHOD OF TREATING CANCER MERCK & CO., INC. (US) 2003-10-16 WO disclosed
WO-2003039460-A2 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2003-05-15 WO disclosed
WO-2000059930-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 2000-10-12 WO disclosed